查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370911

隱球菌病治療市場，- 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按治療、按配銷通路、按地區、按競爭細分。

Cryptococcosis Therapeutics Market, - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Treatment, By Distribution Channel, By Region, By Competition.
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022年全球隱球菌病治療市值為46.7億美元，預計到2028年將呈現穩定成長，年複合成長率為4.34%，預計2028年將達到60.4億美元。隱球菌病主要表現為肺部和中樞神經系統感染，表現出從輕微的呼吸道問題到嚴重的神經系統併發症的症狀。致病真菌常見於環境中，特別是在被鳥糞污染的土壤中。吸入後，真菌孢子會導致感染，特別是對於易受此類疾病影響的個體。在愛滋病毒/愛滋病流行、器官移植和其他免疫抑制狀態等因素的推動下，免疫功能低下患者的盛行率不斷增加，大大加劇了隱球菌病負擔的不斷上升。隨著研究工作不斷產生改進的治療方案，隱球菌病治療市場有望成長。製藥公司、學術機構和公共衛生組織的合作對於推動這些創新至關重要。隨著新型抗真菌藥物、聯合療法和製劑的出現，受隱球菌病影響的個體的前景預計將得到改善，從而提高他們的生活品質和生存率。

主要市場促進因素

免疫功能低下疾病盛行率的上升推動了隱球菌病治療市場：近年來，患有免疫功能低下疾病的人數顯著增加。全球愛滋病毒/愛滋病流行仍是隱球菌病流行的重要因素。儘管愛滋病毒治療和預防方面取得了長足進步，但許多人仍然無法獲得足夠的醫療保健，使他們容易受到隱球菌病等機會性感染。器官移植和癌症治療的日益普及為患者帶來了新的希望，同時削弱了他們的免疫系統。隨著醫學進步延長了器官移植受者和癌症倖存者的壽命，免疫系統受損的人口正在增加。免疫功能低下個體中隱球菌病患病率的上升趨勢促進了隱球菌病療法的發展。因此，該市場見證了研發工作的激增。製藥公司正在努力開發更有效、毒性更低且可供更廣泛患者群體使用的藥物。隱球菌病的著名治療選擇包括抗真菌藥物，如兩性黴素 B、氟康唑和氟胞嘧啶。然而，這些藥物在功效和潛在副作用方面可能存在局限性，從而推動了對創新治療解決方案的需求。研究人員正在積極探索新型抗真菌化合物、聯合療法和免疫調節劑，以提高治療效果並減輕免疫功能低下患者的隱球菌病負擔。

市場概況
預測期 2024-2028
2022 年市場規模 46.7億美元
2028 年市場規模 60.4億美元
2023-2028 年年複合成長率 4.34%
成長最快的細分市場 氟胞嘧啶
最大的市場 北美洲

公眾健康意識的提高推動了隱球菌病治療市場：公眾健康意識的高漲相應地產生了對有效的隱球菌病治療的需求。這種需求反過來又刺激了隱球菌病治療市場的成長。製藥公司和研究人員已經認知到需要創新療法來對抗這種真菌感染並提高患者的生活品質。隨著市場努力提供更有效的治療方法，研發投資大幅增加。這激發了對新候選藥物、治療方法和臨床試驗的探索。解決全球隱球菌病負擔的迫切性推動了新型抗真菌藥物、聯合療法和免疫調節療法的開發。公共衛生意識引發了學術界、製藥公司和研究機構之間的合作。認知到隱球菌病不僅是一個醫學挑戰，而且是一個社會問題，這促使利益相關者合作開發創新解決方案。研究夥伴關係、政府計劃和非營利組織正在匯集資源來推動隱球菌病治療領域的發展。此外，公共衛生意識的提高吸引了創投家和資助組織的投資。市場大幅擴張的潛力，加上解決危及生命的感染的人道主義方面，為研究和臨床試驗提供了財政支持。

真菌感染的複雜性提出了關鍵挑戰：像隱球菌病這樣的真菌感染非常複雜，需要對真菌生物學、宿主相互作用和抗藥性機制有深刻的了解，才能開發有效的治療方法。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球隱球菌病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依治療（兩性黴素 B、氟胞嘧啶、氟康唑、其他）
    • 按配銷通路（醫院、零售藥局、專科診所、其他）
    • 按地區
    • 按公司分類（前 5 名市場參與者的股份）
  • 市場地圖
    • 按治療
    • 按配銷通路
    • 按地區

第 6 章：北美隱球菌病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療
    • 按配銷通路
    • 按國家/地區

第 7 章：歐洲隱球菌病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療
    • 按配銷通路
    • 按國家/地區

第 8 章：亞太地區隱球菌病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療
    • 按配銷通路
    • 按國家/地區

第 9 章：南美隱球菌病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按配銷通路
    • 按國家/地區

第 10 章：中東和非洲隱球菌病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按配銷通路
    • 按國家/地區

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 治療啟動

第13章：競爭格局

  • 安斯泰來製藥公司
  • 百時美施貴寶公司
  • 格蘭馬克製藥公司
  • 楊森生物技術公司（Johnson & Johnson Services, Inc.）
  • 諾華公司
  • 輝瑞公司
  • 旭化成製藥
  • Sigmapharm 實驗室有限責任公司

第 14 章：策略建議

第 15 章：關於我們與免責聲明

簡介目錄
Product Code: 15909

The Global Cryptococcosis Therapeutics Market, valued at USD 4.67 Billion in 2022, is expected to exhibit steady growth with a CAGR of 4.34% through 2028 and expected to reach USD 6.04 Billion in 2028. Cryptococcosis predominantly manifests as a pulmonary and central nervous system infection, exhibiting symptoms ranging from mild respiratory issues to severe neurological complications. The causative fungus is commonly found in the environment, particularly in soil contaminated by bird droppings. When inhaled, the fungal spores can lead to infections, especially in individuals susceptible to such conditions. The increasing prevalence of immunocompromised patients, driven by factors like the HIV/AIDS epidemic, organ transplants, and other immunosuppressive states, has significantly contributed to the escalating burden of cryptococcosis. As research endeavors continue to yield improved treatment options, the cryptococcosis therapeutics market is poised for growth. Collaborative efforts involving pharmaceutical companies, academic institutions, and public health organizations will be pivotal in advancing these innovations. With the emergence of new antifungal agents, combination therapies, and formulations, the outlook for individuals affected by cryptococcosis is expected to improve, enhancing their quality of life and survival rates.

Primary Market Drivers

Rising Prevalence of Immunocompromised Conditions Drives the Cryptococcosis Therapeutics Market: In recent years, there has been a noticeable surge in the number of individuals grappling with immunocompromised conditions. The global HIV/AIDS epidemic remains a significant contributor to the prevalence of cryptococcosis. Despite strides in HIV treatment and prevention, many individuals still lack access to adequate healthcare, rendering them susceptible to opportunistic infections such as cryptococcosis. The increasing prevalence of organ transplantation and cancer treatments offers newfound hope to patients while simultaneously weakening their immune systems. As medical advancements extend the lifespans of organ transplant recipients and cancer survivors, the population living with compromised immune systems is on the rise. This upward trajectory in cryptococcosis prevalence among immunocompromised individuals has catalyzed the development of cryptococcosis therapeutics. Consequently, this market has witnessed a surge in research and development endeavors. Pharmaceutical companies are striving to create drugs that are more effective, less toxic, and accessible to a broader patient base. Notable treatment options for cryptococcosis include antifungal drugs like amphotericin B, fluconazole, and flucytosine. However, these medications may have limitations in terms of efficacy and potential side effects, driving the need for innovative therapeutic solutions. Researchers are actively exploring novel antifungal compounds, combination therapies, and immune-modulating agents to enhance treatment outcomes and alleviate the burden of cryptococcosis among immunocompromised patients.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 4.67 Billion
Market Size 2028USD 6.04 Billion
CAGR 2023-20284.34%
Fastest Growing SegmentFlucytosine
Largest MarketNorth America

Rising Public Health Awareness Propels the Cryptococcosis Therapeutics Market: The upsurge in public health awareness has correspondingly generated demand for effective cryptococcosis treatments. This demand, in turn, has stimulated growth within the cryptococcosis therapeutics market. Pharmaceutical companies and researchers have recognized the necessity for innovative therapies to combat this fungal infection and enhance patients' quality of life. Investments in research and development have surged substantially as the market endeavors to offer more effective treatments. This has instigated the exploration of new drug candidates, therapeutic approaches, and clinical trials. The development of novel antifungal agents, combination therapies, and immunomodulatory treatments has been driven by the growing urgency to address the global cryptococcosis burden. Public health awareness has sparked collaboration between academia, pharmaceutical firms, and research institutions. The recognition that cryptococcosis is not just a medical challenge but a societal issue has motivated stakeholders to collaborate on innovative solutions. Research partnerships, governmental initiatives, and nonprofit organizations are pooling resources to advance the field of cryptococcosis therapeutics. Furthermore, heightened public health awareness has garnered investment from venture capitalists and funding organizations. The potential for substantial market expansion, coupled with the humanitarian aspect of addressing a life-threatening infection, has resulted in financial support for research and clinical trials.

Complexity of Fungal Infections Presents Key Challenges: Fungal infections like cryptococcosis are intricate, requiring a profound understanding of fungal biology, host interactions, and resistance mechanisms to develop effective treatments.

Clinical Trial Design Poses Challenges: Conducting clinical trials for antifungal drugs is challenging due to the need for specialized patient populations and appropriate study endpoints.

Affordability and Access Remain Significant Challenges: Ensuring that innovative treatments are affordable and accessible, particularly in resource-limited settings, remains a crucial challenge.

Technological Advancements Drive Market Trends: Advancements in diagnostic techniques have revolutionized cryptococcosis detection, leading to earlier and more accurate diagnoses. Molecular diagnostic methods like polymerase chain reaction (PCR) have enabled the detection of Cryptococcus DNA in patient samples. PCR amplifies specific DNA sequences, enabling the detection of even small amounts of fungal DNA. This technique's sensitivity allows for the identification of the fungus in blood or cerebrospinal fluid, facilitating swift diagnosis and treatment initiation. Antigen detection assays have proven valuable for diagnosing cryptococcosis. These assays identify specific fungal antigens, such as Cryptococcus' capsular polysaccharide, in patient samples. Antigen detection tests are highly sensitive and can be conducted on blood or cerebrospinal fluid, aiding in early infection detection. Advanced imaging techniques like computed tomography (CT) and magnetic resonance imaging (MRI) have enhanced the visualization of fungal infections within the body, especially when they have spread to the central nervous system.

Segmental and Regional Insights: The Flucytosine segment dominated the Cryptococcosis Therapeutics market in 2022 and is predicted to continue its expansion. Hospitals, particularly in North America, play a pivotal role in prompt cryptococcosis diagnosis and treatment, owing to their advanced healthcare infrastructure.

Key Market Players

  • Astellas Pharma Inc
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals
  • Janssen Biotech Inc.( Johnson & Johnson Services, Inc.)
  • Novartis AG
  • Pfizer Inc
  • Asahi Kasei Pharma
  • Sigmapharm Laboratories LLC

Report Scope:

  • In this report, the Global Cryptococcosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Cryptococcosis Therapeutics Market, By Treatment:

  • Amphotericin B
  • Flucytosine
  • Fluconazole
  • Other

Cryptococcosis Therapeutics Market, By Distribution Channel:

  • Hospitals
  • Retail Pharmacies
  • Specialty Clinics
  • Others

Cryptococcosis Therapeutics Market, By Region:

  • North America
  • Asia-Pacific
  • Europe
  • Middle East & Africa
  • South America

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Cryptococcosis Therapeutics Market.

Available Customizations:

  • Global Cryptococcosis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cryptococcosis Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Amphotericin B, Flucytosine, Fluconazole, Others)
    • 5.2.2. By Distribution Channel (Hospitals, Retail Pharmacies, Specialty Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (Shares of Top 5 Market Players)
  • 5.3. Market Map
    • 5.3.1. By Treatment
    • 5.3.2. By Distribution Channel
    • 5.3.3. By Region

6. North America Cryptococcosis Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
      • 6.2.3.1. United States Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.1.1. Market Size & Forecast
        • 6.2.3.1.1.1. By Value
        • 6.2.3.1.2. Market Share & Forecast
        • 6.2.3.1.2.1. By Treatment
        • 6.2.3.1.2.2. By Distribution Channel
      • 6.2.3.2. Canada Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.2.1. Market Size & Forecast
        • 6.2.3.2.1.1. By Value
        • 6.2.3.2.2. Market Share & Forecast
        • 6.2.3.2.2.1. By Treatment
        • 6.2.3.2.2.2. By Distribution Channel
      • 6.2.3.3. Mexico Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.3.1. Market Size & Forecast
        • 6.2.3.3.1.1. By Value
        • 6.2.3.3.2. Market Share & Forecast
        • 6.2.3.3.2.1. By Test
        • 6.2.3.3.2.2. By Distribution Channel

7. Europe Cryptococcosis Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2.
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
      • 7.2.4.1. France Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
        • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Treatment
        • 7.2.4.1.2.2. By Distribution Channel
      • 7.2.4.2. Germany Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
        • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Treatment
        • 7.2.4.2.2.2. By Distribution Channel
      • 7.2.4.3. United Kingdom Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
        • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Treatment
        • 7.2.4.3.2.2. By Distribution Channel
      • 7.2.4.4. Italy Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
        • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Treatment
        • 7.2.4.4.2.2. By Distribution Channel
      • 7.2.4.5. Spain Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
        • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Treatment
        • 7.2.4.5.2.2. By Distribution Channel

8. Asia Pacific Cryptococcosis Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
      • 8.2.3.1. China Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.1.1. Market Size & Forecast
        • 8.2.3.1.1.1. By Value
        • 8.2.3.1.2. Market Share & Forecast
        • 8.2.3.1.2.1. By Treatment
        • 8.2.3.1.2.2. By Distribution Channel
      • 8.2.3.2. India Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.2.1. Market Size & Forecast
        • 8.2.3.2.1.1. By Value
        • 8.2.3.2.2. Market Share & Forecast
        • 8.2.3.2.2.1. By Treatment
        • 8.2.3.2.2.2. By Distribution Channel
      • 8.2.3.3. South Korea Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.3.1. Market Size & Forecast
        • 8.2.3.3.1.1. By Value
        • 8.2.3.3.2. Market Share & Forecast
        • 8.2.3.3.2.1. By Treatment
        • 8.2.3.3.2.2. By Distribution Channel
      • 8.2.3.4. Japan Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.4.1. Market Size & Forecast
        • 8.2.3.4.1.1. By Value
        • 8.2.3.4.2. Market Share & Forecast
        • 8.2.3.4.2.1. By Treatment
        • 8.2.3.4.2.2. By Distribution Channel
      • 8.2.3.5. Australia Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.5.1. Market Size & Forecast
        • 8.2.3.5.1.1. By Value
        • 8.2.3.5.2. Market Share & Forecast
        • 8.2.3.5.2.1. By Treatment
        • 8.2.3.5.2.2. By Distribution Channel

9. South America Cryptococcosis Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2.
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. Brazil Cryptococcosis Therapeutics Market Outlook
        • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
        • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Treatment
        • 9.2.4.1.2.2. By Distribution Channel
      • 9.2.4.2. Argentina Cryptococcosis Therapeutics Market Outlook
        • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
        • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Treatment
        • 9.2.4.2.2.2. By Distribution Channel
      • 9.2.4.3. Colombia Cryptococcosis Therapeutics Market Outlook
        • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
        • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Treatment
        • 9.2.4.3.2.2. By Distribution Channel

10. Middle East & Africa Cryptococcosis Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
      • 10.2.3.1. South Africa Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.1.1. Market Size & Forecast
        • 10.2.3.1.1.1. By Value
        • 10.2.3.1.2. Market Share & Forecast
        • 10.2.3.1.2.1. By Treatment
        • 10.2.3.1.2.2. By Distribution Channel
      • 10.2.3.2. Saudi Arabia Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.2.1. Market Size & Forecast
        • 10.2.3.2.1.1. By Value
        • 10.2.3.2.2. Market Share & Forecast
        • 10.2.3.2.2.1. By Treatment
        • 10.2.3.2.2.2. By Distribution Channel
      • 10.2.3.3. UAE Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.3.1. Market Size & Forecast
        • 10.2.3.3.1.1. By Value
        • 10.2.3.3.2. Market Share & Forecast
        • 10.2.3.3.2.1. By Treatment
        • 10.2.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Treatment Launches

13. Competitive Landscape

  • 13.1. Astellas Pharma Inc
  • 13.2. Bristol-Myers Squibb Company
  • 13.3. Glenmark Pharmaceuticals
  • 13.4. Janssen Biotech Inc.( Johnson & Johnson Services, Inc.)
  • 13.5. Novartis AG
  • 13.6. Pfizer Inc
  • 13.7. Asahi Kasei Pharma
  • 13.8. Sigmapharm Laboratories LLC

14. Strategic Recommendations

15. About us & Disclaimer